License Compliance definition

License Compliance. (This section shall replace section 10.5 of the End User License Agreement).
Sample 1Sample 2
License Compliance if You are a business, company or organization, You agree that upon request from CSS You will within thirty (30) days document and certify that the use of any and all CSS Software at the time of the request is in conformity with Your valid Software License Agreement. Discontinuing or Modifying Services: You acknowledge that CSS has the right to discontinue the manufacture and development of any of the Software and the support for that Software, in its sole discretion at any time, including the distribution of older Software versions. Notwithstanding the foregoing, if CSS discontinues the manufacture and support for a specific Software, Support for any remaining Software covered by this Agreement shall not be adversely affected. CSS reserves the right to alter the AMS services, in its sole discretion but in no event, shall such alterations result in: (a) diminished support from the level of support set forth herein;
Sample 1
License Compliance if You are a business, company or organization, You agree that upon request from CSS You will within thirty (30) days document and certify that the use of any and all CSS Software at the time of the request is in conformity with Your valid Software License Agreement. Discontinuing or Modifying Services: You acknowledge that CSS has the right to discontinue the manufacture and development of any of the Software and the support for that Software, in its sole discretion at any time, including the distribution of older Software versions. Notwithstanding the foregoing, if CSS discontinues the manufacture and support for a specific Software, Support for any remaining Software covered by this Agreement shall not be adversely affected. CSS reserves the right to alter the AMS services, in its sole discretion but in no event, shall such alterations result in: (a) diminished support from the level of support set forth herein; (b) materially diminished obligations for CSS; or (c) Your materially diminished rights. Governing Law: this Agreement will be governed by and construed in accordance with the laws of the State of Nevada, USA. The United Nations Convention on Contracts for the International Sale of Goods will not apply. You and CSS agree to submit to the exclusive jurisdiction of, and venue in, the courts in Las Vegas, Nevada, in any dispute arising out of or relating to this Agreement.
Sample 1

Examples of License Compliance in a sentence

  • Licensor or an Auditor (as defined below) has the right to verify Licensee’s compliance with this License Agreement (and please see Micro Focus License Compliance Charter - xxxx://xxxxxxxxxxx.xxxxxxxxxx.xxx/licensing/licVerification.aspx).

  • Licensor or an Auditor (as defined below) has the right to verify Your compliance with this Agreement and the Micro Focus License Compliance Charter - xxxx://xxxxxxxxxxx.xxxxxxxxxx.xxx/licensing/licVerification.aspx).

  • The detailed subcategories of requirements for License Compliance of FLOSS components are demon- strated in Table 4.

  • R., De Paoli, S., D’Andrea, V., Weiss, M.: License Compliance Issues in Free and Open Source Soft- ware.

  • Licensor or an Auditor (as defined below) has the right to verify Licensee’s compliance with the licenses issued under Product Orders, the applicable ALAs and this Agreement (please see Micro Focus License Compliance Charter at xxxx://xxxxxxxxxxx.xxxxxxxxxx.xxx/licensing/licVerification.aspx, which can also be provided by Licensor at Licensee’s request).

  • The costs of acquiring the land in regard to valuation and conveyance will be in the vicinity of $1,200 per parcel.

  • Licensor or an Auditor (as defined below) has the right to verify Licensee’s compliance with this License Agreement (and please see Micro Focus License Compliance Charter - http://supportline.microfocus.com/licensing/licVerification.aspx).

  • Licensee is aware that Licensor may embed the Program(s) with third-party license compliance technology (“License Compliance Technology”) that reports information to both the third-party licensor of the License Compliance Technology (“Technology Provider”) and Licensor relating to unique user and network identification with respect to the use of the Program(s) (including, but not limited to, user names, e-mail addresses, IP addresses and the domains from which the use of the Program(s) originated).

  • OrganizationPhoneE-mail / WebsiteCity of Cambridge Attn: Business License Compliance Officer Office of the City ClerkPO Box 669, 50 Dickson St.Cambridge, Ontario N1R 5W8 519-740-4680 ext.

  • Identification Information collected by the License Compliance Technology includes geographic location data, usernames, e-mail addresses, IP addresses, hostname, MAC addresses, and the domains from which the use of the Program(s) originated.


More Definitions of License Compliance

License Compliance. If You are a business, company or organization, You agree that upon request from CSS You will within thirty (30) days document and certify that the use of any and all CSS Software at the time of the request is in conformity with Your valid Software License Agreement.
Sample 1

Related to License Compliance

  • License Key means a unique key-code that enables Licensee to run Software subject to the obtained User Pack.

  • LEGAL COMPLIANCE This Agreement and any transaction with, or payment to, you pursuant to the terms hereof is conditioned on your representation to us that, as of the date of this Agreement you are, and at all times during its effectiveness you will be, a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934 (or other financial institution) and not otherwise required to register as a broker or dealer under such Act. You agree to notify us promptly in writing if this representation ceases to be true. You also agree that, regardless of whether you are a member of the NASD, you will comply with the rules of the NASD, including, in particular, Sections 2310, IM 2310-2, and 2830 of the NASD Conduct Rules, and that you will maintain adequate records with respect to your customers and their transactions, and that such transactions will be without recourse against you by your customers. We recognize that, in addition to applicable provisions of state and federal securities laws, you may be subject to the provisions of the Xxxxx-Xxxxxxxx Act and other laws governing, among other things, the conduct of activities by federal and state chartered and supervised financial institutions and their affiliated organizations. As such, you may be restricted in the activities that you may undertake and for which you may be paid, and, therefore, we recognize that you will not perform activities that are inconsistent with your statutory and regulatory obligations. Because you will be the only one having a direct relationship with the customer, you will be responsible in that relationship for insuring compliance with all laws and regulations, including those of all applicable federal and state regulatory authorities and bodies having jurisdiction over you or your customers to the extent applicable to securities purchases hereunder.

  • Year 2000 Compliance has the meaning set forth in section 17.29 of the Management Agreement.

  • Compliance Review means an inspection of the home, grounds, and files to determine compliance with these regulations.

  • Labor compliance agreement means an agreement entered into between a contractor or subcontractor and an enforcement agency to address appropriate remedial measures, compliance assistance, steps to resolve issues to increase compliance with the labor laws, or other related matters.

  • Assessment of Compliance As defined in Section 3.21.

  • Non-Compliance means failure/refusal to comply the terms and conditions of the tender;

  • major non-compliance outcome notification means a notification received by a council under section 19N(3) or (4) of the Food Act 1984, or advice given to council by an authorized officer under that Act, of a deficiency that does not pose an immediate serious threat to public health but may do so if no remedial action is taken

  • Safety compliance facility means a licensee that is a commercial entity that receives marihuana from a marihuana facility or registered primary caregiver, tests it for contaminants and for tetrahydrocannabinol and other cannabinoids, returns the test results, and may return the marihuana to the marihuana facility.

  • Radiopharmaceutical quality assurance means, but is not limited to, the performance of appropriate chemical, biological, and physical tests on potential radiopharmaceuticals and the interpretation of the resulting data to determine their suitability for use in humans and animals, including internal test assessment, authentication of product history, and the keeping of proper records.

  • Clinical laboratory means a facility for the microbiological, serological, chemical, hematological, radiobioassay, cytological, immunohematological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or assessment of a medical condition.

  • Biologics License Application or “BLA” means an application requesting permission from the FDA to introduce, or deliver for introduction, a biological product into interstate commerce, or any similar application or submission for marketing authorization of a product filed with a Regulatory Authority to obtain Regulatory Approval for such product in a country or group of countries.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase 4 Clinical Trial means a Clinical Study in any country which is conducted after Regulatory Approval of a product has been obtained from an appropriate Regulatory Authority, consisting of trials conducted voluntarily for enhancing marketing or scientific knowledge of an approved indication and trials conducted due to request or requirement of a Regulatory Authority.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Clinical evaluation means a systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device in order to verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer;

  • Web Site Accessibility Standards/Specifications means standards contained in Title 1 Texas Administrative Code Chapter 206.

  • Diagnostic clinical procedures manual means a collection of written procedures that describes each method (and other instructions and precautions) by which the licensee performs diagnostic clinical procedures; where each diagnostic clinical procedure has been approved by the authorized user and includes the radiopharmaceutical, dosage, and route of administration.

  • Quality Improvement means a focus on activities to improve performance above minimum standards and reasonably expected levels of performance, quality and practice.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Clinical nurse specialist means a registered nurse with relevant post-basic qualifications and 12 months’ experience working in the clinical area of his/her specified post-basic qualification, or a minimum of four years’ post-basic registration experience, including three years’ experience in the relevant specialist field and who satisfies the local criteria.

  • Manufacturing Know-How means, with respect to the Product or any Variant thereof, the technology, data, designs, processes, methods, specifications and other know-how used in connection with the formulation, manufacture, labeling, packaging, quality control, release testing, and production of the Product, and all ingredients used therein and portions thereof.

  • CREFC® Intellectual Property Royalty License Fee With respect to each Mortgage Loan (including any REO Mortgage Loan) and for any Distribution Date, the amount accrued during the related Interest Accrual Period at the CREFC® Intellectual Property Royalty License Fee Rate on, in the case of the initial Distribution Date, the Cut-Off Date Balance of such Mortgage Loan and, in the case of any subsequent Distribution Date, the Stated Principal Balance of such Mortgage Loan as of the close of business on the Distribution Date in the related Interest Accrual Period; provided that such amounts shall be computed for the same period and on the same interest accrual basis respecting which any related interest payment due or deemed due on the related Mortgage Loan is computed and shall be prorated for partial periods. For the avoidance of doubt, the CREFC® Intellectual Property Royalty License Fee shall be payable from the Lower-Tier REMIC.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Collaborative pharmacy practice agreement means a written and signed